Sharecafe

Prescient Therapeutics Expands US Clinical Trial

Thumbnail
PTX-100 trial site opens in the United States for r/r CTCL

Prescient Therapeutics (ASX: PTX), an oncology biotech company focused on developing novel therapies, has announced the commencement of US patient recruitment for its Phase 2a clinical trial of PTX-100. The trial targets patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL). Prescient Therapeutics is focused on developing personalised, cell therapy approaches to cancer, with a vision to eliminate cancer as a cause of death. The company’s lead programs are PTX-100 and OmniCAR, both designed to improve outcomes for cancer patients.

The Massey Comprehensive Cancer Centre at Virginia Commonwealth University, a top-ranked cancer research centre in the US, has joined the trial. This US site complements the existing three Australian sites where patient enrolment is underway. Professor Said Sebti, Prescient’s scientific founder, expressed enthusiasm about the US site activation, highlighting its significance in bringing the potential benefits of PTX-100 to a broader patient base.

Prescient is funding the Phase 2 trial and potential regulatory approval of PTX-100 through a $7 million share purchase plan. The company extended the closing date of the plan to 22 July after receiving requests for additional time from shareholders. Proceeds from the raising will be used to support the advancement of PTX-100 Phase 2 clinical trials toward regulatory approval.

PTX-100 is a first-in-class targeted therapy that blocks a cancer growth enzyme, geranylgeranyltransferase type 1 (GGT-1), by disrupting the ‘Ras’ cellular signalling pathway. The therapy has demonstrated promising results in earlier clinical trials, showing positive data for patients with relapsed or refractory cancers. The Phase 2a trial will assess dose optimisation in 40 patients, while a subsequent Phase 2b trial will focus on efficacy and safety in another 75 patients.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories

Subscribe

get the latest